|
 |
GefitinibThis page contains recent news articles, when available, and an overview of Gefitinib but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.The author forecasts AstraZeneca's Iressa (gefitinib) will overcome its disappointing start in the NSCLC arena following positive results of two recent ... Earthtimes (press release) 05.01.2010 - In bestimmten Fällen: Tyrosinkinasehemmer bei nicht-kleinzelligem ... - 05 Jan 2010 Dem Studienbericht in der Fachzeitschrift The Lancet Oncology zufolge verlängert sich durch Gefitinib die Zeit bis zum weiteren Fortschreiten der Krankheit. ... DKG Krebsgesellschaft â€œê°„ì ‘í?¡ì—° í??암환ìž?는 ì¹˜ë£Œì œ 효과ë?„ 낮다â€? - 05 Jan 2010 ...ìƒ?피세í?¬ì„±ìž¥ì?¸ìž?ì?˜ ìœ ì „ìž? ë?Œì—°ë³€ì?´ëŠ” ì?´ë ˆì‚¬(gefitinib)나 타세바(erlotinib)와 ê°™ì?€ í‘œì ?ì¹˜ë£Œì œì?˜ 주요 타깃ì?´ ë?˜ëŠ” ë°”ì?´ì˜¤ë§ˆì»¤ë¡œ ë?Œì—°ë³€ì?´ê°€ 존재하면 ì?´ëŸ¬í•œ í‘œì ? ... YTN Gefitinib improved survival vs. cisplatin/docetaxel in patients with NSCLC ... - Dec 21, 2009 Patients with non–small cell lung cancer who have epidermal growth factor receptor mutations had superior PFS when assigned to gefitinib compared with ... HemOncToday Reportlinker Adds Lung Cancer Therapeutics Market Outlook and Pipeline Analysis - Dec 17, 2009 Arrowhead forecasts AstraZeneca's Iressa (gefitinib) will overcome its disappointing start in the NSCLC arena following positive results of two recent Phase ... PR Newswire (press release) Successes and challenges in personalized medicine - Dec 21, 2009 They hypothesized that patients with those mutations show greater sensitivity to gefitinib. Sure enough, a recent study showed that gefitinib worked in more ... Farm and Dairy The Changing Face of Medicine, 1984-2009: - Dec 29, 2009 Erlotinib (Tarceva) and gefitinib (Iressa) also appeared on the market, but it wasn't until about 2004 that researchers began to figure out why these two ... MedPage Today Genomic medicine: "Nothing to see here", says the Government - Dec 14, 2009 He pointed out that genetically-targeted cancer drugs such as cetuximab and gefitinib are already becoming available, but that poor NHS provision of the ... Times Online Boehringer Ingelheim Initiates First Phase III Clinical Trial in Ovarian Cancer - Dec 20, 2009 ...placebo plus BSC in non-small cell lung cancer patients who have experienced a failure of treatment with erlotinib or gefitinib (EGFR TKI failures). ... AUTO-MOBI.info Una nueva familia de fármacos contra el cáncer de pulmón funciona en el ... - Dec 23, 2009 ...que además son portadores de una mutación en el gen EGFR se beneficiaban de la acción de una familia de fármacos especÃfica: erlotinib y gefitinib. ... elmundo.es Erst Gentest, dann Therapie - Dec 26, 2009 Die japanischen Mediziner verglichen Gefitinib mit etablierter Chemotherapie bei Patienten mit einer EGFR-Mutation. Im Mittel konnte das Wachstum des Tumors ... Tagesspiegel Silvia Ojanguren - Dec 22, 2009 Entre las terapias nuevas para tratar el cáncer de pulmón de células no pequeñas están las denominadas de blanco molecular como gefitinib de AstraZeneca, ... El Universal (México) Personenbezogene Arznei für wirksame Krebstherapie - Dec 17, 2009 Der jüngste Neuzugang unter den personalisierten Krebsarzneien sind die Präparate Gefitinib vom Hersteller AstraZeneca und Erlotinib von Roche, ... VDI Nachrichten Lungenkrebs: Pfizer bricht Studie nach Todesfällen ab - Dec 30, 2009 Der Rezeptor soll aber auch an der Resistenzentwicklung gegen EGFR-Inhibitoren (wie Gefitinib, Erlotinib, Cetuximab oder Panitumumab) beteiligt sein. ... Deutsches Ärzteblatt Krebs: Häufige Hautinfektionen nach EGFR-Inhibitoren - Dec 10, 2009 ...die den EGFR blockieren, aber auch Gefitinib (Iressa®) und Erlotinib (Tarceva®), welche die Weiterleitung der Wachstumssignale in der Krebszelle hemmen. ... Deutsches Ärzteblatt Report Highlights Cancer Advances - Nov 9, 2009 Another targeted agent, gefitinib (Iressa), did not improve survival compared with methotrexate in patients with recurrent squamous-cell carcinoma of the ... MedPage Today NCI Seeking Participants for New Mesothelioma Drug Trial - Oct 19, 2009 The National Cancer Institute (NCI) is currently looking for participants for a clinical drug trial testing the effectiveness of the cancer drug gefitinib ... Mesothelioma.net Blog ASCO Releases Annual Progress Report on Top Cancer Research Advances - Nov 11, 2009 ...specific subset of patients with non-small cell lung cancer ( NSCLC ) who benefit from first-line treatment with the targeted drug gefitinib ( Iressa ). ... Media Newswire (press release) Neoadjuvant Taxotere® and ADT Well Tolerated in High-risk Prostate Cancer - Oct 27, 2009 Researchers from the Virginia Mason Medical Center in Seattle, Washington, have also reported that neoadjuvant Taxotere and Iressa® (gefitinib) is well ... Cancer Consultants Comparing notes: UK's cancer leaders discuss the latest advances - Oct 28, 2009 For example, a trial in Japanese patients found a 100% rate of EGFR mutations, and a 66% overall response to therapy targeted at this marker (gefitinib). ... Pharmafocus EN PERÚ SE DIAGNOSTICAN 1500 CASOS DE CÃ?NCER DE PULMÓN AL AÑO - Nov 9, 2009 First line gefitinib versus first line chemotherapy by CBDCA plus paclitaxel in NSCLC patients with EGFR mutations: a phase III study (002) by North East ... Press Perú Erst der Gentest, dann die Chemotherapie - Oct 19, 2009 Jüngste Beispiele für personalisierte Krebsmedikamente sind die Präparate Gefitinib vom Hersteller AstraZeneca und Erlotinib von Roche, die eine bestimmte ... WELT ONLINE 美 'ì?´ë ˆì‚¬', 'ë¯¸ë“œë¡ ' 등 ê²€ì¦?실패 - Oct 27, 2009 ...ë¯¸êµ FDAê°€ 'ì?´ë ˆì‚¬'(Iressa, gefitinib), 'ë¯¸ë“œë¡ '(midodrine) 등 조기 승ì?¸í•œ ì?˜ì•½í’ˆì?˜ 후ì†? ê²€ì¦?ì—? 실패했다는 지ì ?ì?´ 나왔다. ë¯¸êµ ì •ë¶€ ê°?사ì›?(GAO)ì?€ ë³´ê³ ì„œë¥¼ ... 디지틀보사 Gefitinib is more effective in never-smokers with non-small-cell lung... - Jun 7, 2005 Correspondence: Dr EH Tan, Department of Medical Oncology, National Cancer Centre, 11 Hospital Drive, Singapore 169610, Singapore. E-mail: dmoteh@nccs.com. ... Nature.com Gefitinib Edges Chemotherapy for Advanced NSCLC - Nov 20, 2008 By Crystal Phend, Staff Writer, MedPage Today. HOUSTON, Nov. 20 - For second-line treatment of non-small-cell lung cancer (NSCLC), oral gefitinib (Iressa) ... MedPage Today Gefitinib potentiates myeloid cell differentiation by ATRA - Feb 28, 2008 Acute myeloid leukemias (AMLs) are characterized by a variety of genetic defects that contribute to the failure of these cells to undergo differentiation to ... Nature.com … is the best way to manage patients treated with gefitinib for non... - Mar 21, 2005 Shah NT et al. (2005) Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 23: 165–174 PubMed ... Nature.com Milestone 24 : Nature Milestones in Cancer - Apr 1, 2006 Designing targeted drugs for more common and complex cancers, however, presents added challenges, as illustrated by the story of gefitinib (Iressa; ... Nature.com Lung Cancer - Non-Small Cell Chemotherapy Treatments - Lung Cancer - … - Aug 5, 2008 These patients have benefited from gefitinib in the past, or they are enrolled in a ... Erlotinib (Tarceva) is in the same medication class as gefitinib. ... New York Times EGFR point mutation confers resistance to gefitinib in a patient with... - Apr 11, 2005 Kobayashi S et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786–792 PubMed ... Nature.com … diagnostics add to clinical characteristics in selecting patients... - Aug 14, 2007 ...(2007) Prospective study of gefitinib in epidermal growth factor receptor ... To assess gefitinib sensitivity in smoking and nonsmoking patients with NSCLC ... Nature.com AstraZeneca submits EU application for gefitinib in non-small cell... - May 2, 2008 LONDON (Thomson Financial) - AstraZeneca plc, the UK's second-biggest drugmaker, has submitted a marketing application to the European authorities for its ... Forbes Gefitinib response of erlotinib-refractory lung cancer involving... - Oct 23, 2005 Background A 70-year-old Japanese–American woman who had never smoked was diagnosed with stage IV non-small-cell lung cancer with rib metastases. ... Nature.com Gefitinib [mdash] a novel targeted approach to treating cancer :... - Aug 2, 2007 Twenty years after the epidermal growth factor receptor (EGFR) was identified as a potential anticancer target, the EGFR inhibitor gefitinib (Iressa; ... Nature.com Lessons from the lung for targeted anticancer drugs - Aug 2, 2007 This is good news for AstraZeneca as gefitinib received an updated label from the FDA ... Development of gefitinib began in the late 1990s with the aim of ... Nature.com Identification of EGFR kinase domain mutations among lung cancer … - Mar 8, 2005 Initially, the response rate to gefitinib was poor (10%) among patients in the ... Biochemically, mutated EGFRs are more sensitive to gefitinib than to wild ... Nature.com Gefitinib (Systemic).(Drug overview) - Aug 1, 2006 Gefitinib (ge-FI-tye-nib) belongs to the group of medicines called antineoplastics. It is used to treat non-small cell lung cancer after the failure of ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com The role of genetic testing in the prediction of response to EGFR... - Oct 24, 2008 It is noteworthy that gefitinib failed to show a significant survival benefit in a phase ... Multi-institutional randomized phase II trial of gefitinib for ... Nature.com Drug combination helps certain breast cancer cases - May 1, 2007 The third drug was gefitinib, sold by AstraZeneca under the brand name Iressa. All the drugs are monoclonal antibodies -- engineered human immune system ... Reuters Gefitinib (ZD1839, Iressaâ„¢) as palliative treatment in recurrent or … - Oct 10, 2005 To assess the level of activity and toxicity of gefitinib (ZD1839, Iressaâ„¢) in a population of patients with locally recurrent and/or metastatic head and ... Nature.com Daily Gefitinib Plus Weekly Paclitaxel in Non-Small-Cell Lung Cancer ... - Nov 10, 2006 By Chris Berrie. PRAGUE, CZECH REPUBLIC -- November 10, 2006 -- The combination of gefitinib and paclitaxel shows moderate activity and low toxicity as a ... DG News Gefitinib shows promise in treating Asian nonsmokers with lung cancer - Sep 16, 2008 Washington, Sept 16 : Researchers in Hong Kong have suggested that gefitinib should be considered a first-line therapy for non-smoking Asian patients with ... Turkmenistan News Clinical trial of gefitinib for advanced lung cancer closes early - Apr 19, 2005 Researchers have closed a randomized clinical trial comparing gefitinib (Iressa) vs. placebo following chemotherapy and radiation for patients with ... News-Medical.net IASLC: Gefitinib Matches Docetaxel as Second-Line Therapy for NSCLC - Sep 5, 2007 By Charles Bankhead, Staff Writer, MedPage Today. SEOUL, South Korea, Sept. 5 -- Targeted therapy with the receptor tyrosine kinase inhibitor gefitinib ... MedPage Today … Further Restricts the Indication of Iressa (Gefitinib) to Patients... - Jun 5, 2006 ...in consultation with Health Canada, is informing health care professionals of a new restriction to the indication of Iressa® (gefitinib). ... DG News AstraZeneca's ineffective lung cancer drug may shrink breast tumours ... - May 16, 2005 Of the 28 assigned gefitinib and a placebo, 14 experienced the reduction. 'Gefinitib, combined with an aromatase inhibitor, might have a role in the ... Forbes Gefitinib May Enhance Treatment for Metastatic Breast Cancer - May 20, 2008 NEW YORK -- May 20, 2008 -- According to the results of a phase 2 clinical trial, gefitinib (Iressa) may enhance the effectiveness of hormonal therapy for ... DG News Study reveals how some molecules inhibit growth of lung cancer cells - Mar 14, 2007 ..."We now see that inhibitors such as gefitinib actually bind more tightly to some of the ... They found that two inhibitors – the drug gefitinib (marketed as ... Hindu Genzyme launches lung-cancer gene test - Dec 4, 2006 ...a marker linked to resistance to certain lung-cancer drugs, including the tyrosine kinase inhibitors Tarceva (erlotinib) and Iressa (gefitinib). ... United Press International Phase I Sudy Combining Gefitinib With Docetaxel And Estramustine … - Jun 16, 2006 UroToday.com - Combination docetaxel regimens have been shown to improve overall survival in randomized clinical trial in patients with hormone-refractory ... Medical News Today - Medical News Today (press release) … Application In Europe For EGFR Inhibitor Gefitinib In Locally... - May 5, 2008 The application is based on data from the Phase III INTEREST study, which showed that patients with pre-treated advanced NSCLC who received gefitinib had ... Medical News Today - Medical News Today (press release) Learn about Gefitinib from Consumer Reports Health. - Jan 3, 2007 Gefitinib is used to treat non-small cell lung cancer in people who have already been treated with certain other chemotherapy medications and have not ... consumerreports.org Gefitinib Does Not Improve Survival in Refractory Advanced NSCLC - Oct 27, 2005 NEW YORK OCT 27, 2005 (Reuters Health) - As a second- or third-line therapy for advanced non-small-cell lung cancer (NSCLC), treatment with gefitinib ... Cancerpage.com Treatment Options for the Papulopustular Eruption of Gefitinib - Jan 1, 2007 The authors present a case series of 3 patients in regard to the treatment of folliculitis secondary to gefitinib. All patients had stage IV nonsmall cell ... Free with registration - Journal of Drugs in Dermatology - AccessMyLibrary.com Clinical Trial of Gefitinib for Advanced Lung Cancer Closes Early - May 2, 2005 Researchers have closed a randomized clinical trial comparing gefitinib (Iressa TM) vs. placebo following chemotherapy and radiation for patients with ... emaxhealth.com EGFR Mutations Predict Lung Cancer Response to Gefitinib - Nov 8, 2006 NEW YORK NOV 08, 2006 (Reuters Health) - Screening for EGFR mutations in pleural fluid can be helpful in predicting the outcome of gefitinib treatment for ... Cancerpage.com EGFR mutations and molecularly targeted therapy: a new era in the … - Nov 22, 2005 In phase II trials of gefitinib in patients with pretreated metastatic NSCLC, ... 3 A similarly designed trial examined the efficacy of gefitinib versus ... Nature.com Personalized cancer therapy found valuable - May 21, 2008 Investigators found gefitinib (Iressa) treatment considerably improved the outcomes for non-small-cell-lung-cancer, although additional research is required ... United Press International … Therapy; Gallbladder adenocarcinoma submits to gefitinib due to... - May 3, 2006 ..."Although gefitinib, a selective inhibitor of epidermal growth factor receptor ... In this study, we investigated the mechanism of gefitinib-induced growth ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones FDA: gefitinib (Iressa) does not prolong survival.(Brief Article) - Feb 1, 2005 The FDA issued a statement last December urging patients who take gefitinib (Iressa) to consult their physicians, since gefitinib failed to show in a ... Free with registration - Drug Formulary Review - AccessMyLibrary.com Erlotinib Helps in Lung Cancer after Gefitinib Failure - Jul 5, 2007 By David Douglas. NEW YORK JUL 05, 2007 (Reuters Health) - Acquired resistance to a particular epidermal growth factor receptor (EGFR) tyrosine kinase ... Cancerpage.com Gefitinib safe, effective in pretreated advanced NSCLC - Nov 25, 2008 Oral gefitinib was as effective as docetaxel for the treatment of locally advanced and metastatic non–small cell lung cancer, according to data from a ... HemOncToday … US Label Change for IRESSA(R) (Gefitinib) and New Distribution … - Jun 17, 2005 ...today that after discussions with the US Food and Drug Administration (FDA), the company is making a labeling change to IRESSA(R) (gefitinib tablets). ... RedOrbit Colon Cancer; Colon cancer sensitivity to gefitinib is restored upon... - Sep 19, 2006 ..."Challenging the EGFR positive LoVo cells with gefitinib (1 mcM) resulted in a small ... pInsR and pAkt levels were increased after gefitinib treatment. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones CNS response after erlotinib therapy in a patient with metastatic... - Feb 1, 2007 Erlotinib and gefitinib are tyrosine kinase inhibitors that target the EGFR ... 5 In Asians, response to gefitinib has been consistently more frequent than ... Nature.com How It Works - Jun 4, 2008 Gefitinib is an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TK) that ... Gefitinib is a medication that is taken by mouth (oral). ... WebMD … Mutation in EGFR Gene Linked to Acquired Resistance to Gefitinib - Feb 22, 2005 ..."We are now trying to figure out other possible reasons why gefitinib or erlotinib stop working," Dr. Pao said in a statement. "We also hope to identify ... Cancerpage.com AV-412 Preclinical Efficacy Data Presented at AACR 2006. - Apr 4, 2006 In preclinical studies, AV-412, erlotinib and gefitinib were evaluated independently for cellular phosphorylation of benchmark proteins EGFR, ... Free with registration - PR Newswire - AccessMyLibrary.com HER3 and mutant EGFR meet MET - Oct 25, 2007 The EGFR kinase inhibitor gefitinib prevents phosphorylation of both EGFR and ... 1 isolated gefitinib-resistant clones from HCC827 lung cancer cells which ... Nature.com … and Increased Copy Numbers Predict Gefitinib Sensitivity in Patie - Feb 21, 2006 Of 66 patients with NSCLC who experienced relapse after surgery and received gefitinib, 39 had EGFR mutations. Response rate, time to progression, ... Medscape Measuring medicine: How new technologies could help doctors predict … - Apr 16, 2008 ...“Amphiregulin expression could, in fact, be a suitable biomarker to select patients with EGFR wild-type NSCLC who would be likely to benefit from gefitinib ... eurekalert.org Gefitinib (Systemic). - Oct 27, 2005 Gefitinib (ge-FI-tye-nib) belongs to the group of medicines called antineoplastics. It is used to treat non-small cell lung cancer after the failure of ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Advances in the Management of Advanced Non–Small Cell Lung Cancer … - Sep 2, 2007 The agents currently being studied are bevacizumab, gefitinib, erlotinib, and sunitinib. One of the major research issues concerning targeted therapy is ... Cancer Consultants … which predict the subsets of patients where gefitinib has the... - Nov 15, 2005 PHILADELPHIA – The drug gefitinib (Iressa) was approved by the US Food and Drug ... In June 2005, FDA issued a new label for gefitinib “that limits use to ... eurekalert.org Determining Genetic Signature of Lung Tumours Can Help Guide … - May 20, 2008 Gefitinib, which disables the epidermal growth factor receptor (EGFR) on the surface ... Gefitinib treatment continued indefinitely unless significant side ... DG News Adverse Drug Reaction; Gefitinib-induced interstitial lung disease is... - Apr 26, 2006 According to a study from Japan, "Gefitinib (ZD1839), a small-molecule epidermal growth factor receptor tyrosine kinase inhibitor, is an anticancer agent ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Gefitinib (Iressa) as Second-Line Therapy in Patients With Advanced... - Jul 6, 2005 By Chris Berrie. BARCELONA, SPAIN -- July 6, 2005 -- The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (Iressa) demonstrates a ... DG News GARDEN STATE BRIEFS - Apr 20, 2005 The trials involved a combination of Genasense with gefitinib, which is used in the ... Gefitinib is manufactured by AstraZeneca under the name Iressa. ... Pay-Per-View - Star-Ledger - Factiva, from Dow Jones Gefitinib (Iressa(reg)) Marketing Authorisation Application Withdrawn... - Jan 6, 2005 AstraZeneca today announced that it is withdrawing the European Marketing Authorisation Application (MAA) for IRESSA(reg) (gefitinib) in treating patients ... Medical News Today - Medical News Today (press release) Clinical trial of gefitinib for advanced lung cancer closes early - Apr 18, 2005 Researchers have closed a randomized clinical trial comparing gefitinib (Iressa TM ) vs. placebo following chemotherapy and radiation for patients with ... PsychCentral.com What is the Best Way to Manage Patients Treated With Gefitinib?: … - Jun 28, 2005 Gefitinib is the most extensively studied and widely used small-molecule ... Unlike conventional agents, gefitinib does not cause myelosuppression, ... Medscape Measuring Medicine: How New Technologies Could Help Doctors Predict … - Apr 8, 2008 ..."Amphiregulin expression could, in fact, be a suitable biomarker to select patients with EGFR wild-type NSCLC who would be likely to benefit from gefitinib ... newswise.com Gefitinib in treating patients who are undergoing surgery and/or... - Jan 1, 2007 This phase II trial is studying how well gefitinib works in treating patients ... Condition Intervention Phase Nonmelanomatous Drug: gefitinib Phase II Skin ... Free with registration - Journal of Drugs in Dermatology - AccessMyLibrary.com Cancer Therapy; Lung cancer patients treated with gefitinib exhibited... - Dec 6, 2005 ..."Gefitinib is the first approved EGFR tyrosine-kinase inhibitor indicated for the treatment of patients with locally advanced (IIIB) or metastatic NSCLC ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Results of Phase II Studies Measure Progression Free Survival for … - Jun 4, 2006 In a two-part study, Trial 003 compared the anti-tumor effects of 300 mg of ZACTIMA administered as monotherapy to 250 mg of gefitinib administered as ... Free with registration - PR Newswire - AccessMyLibrary.com Cancer Therapy; ZD6474 arrests the growth of gefitinib-sensitive... - Mar 7, 2005 ..."ZD6474 is a novel, orally available inhibitor of vascular endothelial growth factor (VEGF) receptor-2 (KDR) tyrosine kinase, with additional activity ... Pay-Per-View - Proteomics Weekly - Factiva, from Dow Jones Cancer Therapy; ZD6474 arrests the growth of gefitinib-sensitive... - Mar 11, 2005 ..."ZD6474 is a novel, orally available inhibitor of vascular endothelial growth factor (VEGF) receptor-2 (KDR) tyrosine kinase, with additional activity ... Pay-Per-View - Angiogenesis Weekly - Factiva, from Dow Jones Study identifies possible marker for efficacy of gefitinib in lung... - May 5, 2005 Patients with advanced non-small-cell lung cancer (NSCLC) whose tumor cells contain extra copies of the epidermal growth factor receptor (EGFR) gene may be ... i-newswire.com US Label Change For Cancer Drug Iressa (gefitinib) - Jun 18, 2005 AstraZeneca announced that after discussions with the US Food and Drug Administration (FDA), the company is making a labeling change to IRESSA® (gefitinib ... Medical News Today - Medical News Today (press release) Revised GL on Use of Gefitinib Reviewed - Mar 28, 2005 Korosho held the third meeting of its Study Group on Gefitinib on March 17 to discuss the revised version of the Guidelines on the Use of Gefitinib compiled ... Pay-Per-View - Pharma Japan - Factiva, from Dow Jones Study describes the first known mutation to occur in lung cancer... - Mar 1, 2005 These mutations have shown increased sensitivity to gefitinib (Iressa) and erlotinib (Tarceva), drugs targeting the gene. To understand better the role of ... News-Medical.net Subset of ovarian cancer patients responsive to Iressa identified,... - Apr 22, 2005 Someday, we'll be able to sequence key genes in ovarian tumors to identify the women who would be responsive to gefitinib or other targeted therapies." ... i-newswire.com Fox Chase Cancer Center researchers identify subset of ovarian cancer... - Apr 14, 2005 Someday, we'll be able to sequence key genes in ovarian tumors to identify the women who would be responsive to gefitinib or other targeted therapies." ... PsychCentral.com Petition to the FDA to remove the cancer drug gefitinib (IRESSA) from... - Mar 4, 2005 Public Citizen, representing 150000 consumers nationwide, petitions the Food and Drug Administration (FDA) to remove the drug Iressa (gefitinib; ... Public Citizen - Auto Safety & Consumer... Study identifies possible marker for efficacy of gefitinib in lung... - Apr 5, 2005 Patients with advanced non–small-cell lung cancer (NSCLC) whose tumor cells contain extra copies of the epidermal growth factor receptor (EGFR) gene may be ... innovations report - Innovations-Report Study identifies possible marker for efficacy of gefitinib in lung... - Apr 28, 2005 Patients with advanced nonñsmall-cell lung cancer (NSCLC) whose tumor cells contain extra copies of the epidermal growth factor receptor (EGFR) gene may be ... PsychCentral.com IBPL to market Gefitinib in India - Jun 15, 2008 Intas Biopharmaceuticals Limited (IBPL) is to market lung cancer drug, gefitinib, under brand name 'Geffy', in the Indian market. IBPL will market Geffy for ... Express Pharma Mechanism of Resistance to Targeted Therapy in Lung Cancer Patients - Feb 18, 2005 Among these patients, gefitinib works by snugly fitting into the activating pocket of the protein like a key into a keyhole, blocking the growth signals and ... newswise.com Treatments have same target, different responses for lung cancer... - Aug 21, 2005 However, gefitinib was more effective than cetuximab at inhibiting cell growth ... They found that all patients displayed partial responses to gefitinib in ... i-newswire.com Study identifies mechanism of resistance to targeted therapy in lung ... - Feb 23, 2005 Among these patients, gefitinib works by snugly fitting into the activating pocket of the protein like a key into a keyhole, blocking the growth signals and ... eurekalert.org Study finds mechanism for drug resistance - Feb 25, 2005 Gefitinib is one of a new generation of cancer drugs that work by ... Gefitinib acts on the receptor for the epidermal growth factor protein (EGFR) to halt ... Cancerfacts.com Study identifies which patients will not respond to treatment with... - Sep 8, 2005 Gefitinib is a drug approved by the Food and Drug Administration to treat ... But gefitinib shrinks tumors in only about 11 percent of patients with non ... innovations report - Innovations-Report Iressa® (gefitinib) 250 mg Tablets Fail to Demonstrate Non-inferiority... - Oct 11, 2007 OTTAWA, CANADA -- October 11, 2007 -- Health Canada has sent a letter to health care professional involved in the Iressa Patient Registry (IPR), ... DG News Health Canada Endorsed Important Safety Information on Iressa (Gefitin... - Dec 12, 2006 ...following discussions with Health Canada, is informing health care professionals of new safety information regarding Iressa (gefitinib). ... DG News Targeted attack: scientists declare war on a protein implicated in... - Aug 27, 2005 Those patterns may explain why gefitinib and similar drugs counter cancers in ... Gefitinib, the first such drug, reduced tumor size in lung cancer patients ... $4.95 - Science News - ECNext DEAR PHARMACIST SUZY COHEN - Jan 20, 2005 The drug Iressa (gefitinib), which was approved in May 2003 for resistant cases of lung cancer, is now under stark criticism. We were led to believe that it ... Pay-Per-View - South Florida Sun - Sentinel - ProQuest Archiver … Lung Cancer; Gene profiling can predict gefitinib susceptibility... - Mar 27, 2005 ..."Gefitinib (Iressa, ZD1839), an inhibitor of epidermal growth factor ... "Our results suggested that sensitivity of a given NSCLC to gefitinib can be ... Pay-Per-View - Medical Devices & Surgical Technology... - Factiva, from Dow Jones … Lung Cancer; Gene profiling can predict gefitinib susceptibility... - Mar 22, 2005 ..."Gefitinib (Iressa, ZD1839), an inhibitor of epidermal growth factor ... "Our results suggested that sensitivity of a given NSCLC to gefitinib can be ... Pay-Per-View - Science Letter - Factiva, from Dow Jones … Lung Cancer; Gene profiling can predict gefitinib susceptibility... - Mar 25, 2005 ..."Gefitinib (Iressa, ZD1839), an inhibitor of epidermal growth factor ... "Our results suggested that sensitivity of a given NSCLC to gefitinib can be ... Pay-Per-View - Drug Week - Factiva, from Dow Jones … Children's Research Hospital, Memphis; Gefitinib demonstrates... - Oct 26, 2005 We conducted a phase I trial of gefitinib, an epidermal growth factor receptor ... "At 400 mg/m2, the median peak gefitinib plasma concentration was 2.2 ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Introgen's Nanoparticle Cancer Therapy Demonstrates Promise in the … - May 18, 2005 In addition, INGN 401 demonstrated synergistic activity with Gefitinib, ... While Gefitinib can produce dramatic responses in a small subset of lung cancer ... AZoNano.com Liver Cancer; Gefitinib prevents hepatocellular carcinoma development... - Apr 11, 2005 ..."Epidermal growth factor receptor (EGFR) binds transforming growth factor a (TGF-alpha) which is mitogenic for hepatocytes. Diverse lines of evidence ... Pay-Per-View - Hepatitis Weekly - Factiva, from Dow Jones Pediatric Oncology; Gefitinib demonstrates efficacy in children with ... - Oct 28, 2005 2005 OCT 28 - (NewsRx.com) -- Scientists observe that gefitinib demonstrates efficacy in children with refractory solid tumors. ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Pediatric Oncology; Gefitinib demonstrates efficacy in children with ... - Oct 24, 2005 2005 OCT 24 - (NewsRx.com) -- Scientists observe that gefitinib demonstrates efficacy in children with refractory solid tumors. ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Liver Cancer; Gefitinib prevents hepatocellular carcinoma development... - Apr 14, 2005 ..."Epidermal growth factor receptor (EGFR) binds transforming growth factor a (TGF-alpha) which is mitogenic for hepatocytes. Diverse lines of evidence ... Pay-Per-View - Gene Therapy Weekly - Factiva, from Dow Jones Predictor of Response to IRESSA(TM) (Gefitinib) Investigated in First... - May 6, 2006 Data announced today at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting further advanced the understanding of the importance of ... presseportal.de Cancer Therapy; Gefitinib treats carcinomatous meningitis in a... - Dec 27, 2005 According to recent research from South Korea, "CM and spinal cord metastases (SCM) are uncommon, yet fatal complication for patients with non-small cell ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Cancer Therapy; ZD6474 arrests the growth of gefitinib-sensitive... - Mar 8, 2005 ..."ZD6474 is a novel, orally available inhibitor of vascular endothelial growth factor (VEGF) receptor-2 (KDR) tyrosine kinase, with additional activity ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Why some lung cancers stop responding to Tarceva and Iressa - Feb 16, 2005 Gefitinib and erlotinib are so-called targeted therapies, ... "We are now trying to figure out other possible reasons why gefitinib or erlotinib stop ... PsychCentral.com Molecular Targeting in the Treatment of Cancer: An Interview With... - Mar 21, 2005 Let's talk about why gefitinib is so disappointing, showing only a 20% response rate. ... It may be that gefitinib could work in only 20% of patients, ... Medscape … to better characterize Iressa.(Tuesday, March 8)(gefitinib drug... - Mar 14, 2005 Looking to better-identify patients for whom Iressa (gefitinib) works, AstraZeneca plc is taking a new tack, according to biomarker study plans reported at ... Free with registration - BioWorld Week - AccessMyLibrary.com … with Interferon Alpha Plus Iressa (Gefitinib) or Gleevec (imatinib... - Nov 22, 2005 PHILADELPHIA, PA -- November 22, 2005 -- In a phase 2 study of interferon alpha (IFN) plus either Gleevec (imatinib mesylate) or Iressa (gefitinib) in ... DG News … III trial for AstraZeneca's (Wilmington, DE) Iressa (gefitinib)... - Jun 1, 2005 A Phase III trial for AstraZeneca's (Wilmington, DE) Iressa (gefitinib) for non-small cell lung cancer closed early for lack of efficacy. Free with registration - Applied Clinical Trials - AccessMyLibrary.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |